Matthew S. Davids, MD, MMSc | Authors


Ibrutinib Plus Umbralisib Induce Survival Benefit in Patients With CLL

August 17, 2020

Matthew Davids, MD, MMSc, discusses the longer-term follow-up data from the phase 3 UNITY-CLL clinical trial, which evaluated umbralisib in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia.

Exploring Durable Responses With Liso-Cel for Relapsed/Refractory CLL

June 11, 2019

Matthew S. Davids, MD, MMSc, discusses the significance of the findings from TRANSCEND CLL 004, a phase I/II trial investigating the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia.